Émile Breault

Émile Breault

Auto-generated profile, based on publicly available information

Émile Breault


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 July 2022 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
YYYang Yue
Yang Yue
LLLier Liu
Lier Liu
LWLi-Jie Wu
Li-Jie Wu
YWYiran Wu
Yiran Wu
LWLing Wang
Ling Wang
FXFei Xu
Fei Xu

1 April 2025 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
ÉBÉmile Breault
Émile Breault
RBRebecca Brouillette
Rebecca Brouillette
THTerry Hebert
Terry Hebert
PSPhilippe Sarret
Philippe Sarret
Elie Besserer-OffroyElie Besserer-Offroy
Elie Besserer-Offroy

22 October 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ALAnnik Lanoie
Annik Lanoie
SFSára Ferková
Sára Ferková
ÉCÉdouard Caron-Duval
Édouard Caron-Duval
JDJuliana C.C. Dallagnol
Juliana C.C. Dallagnol
SDSitan Diarra
Sitan Diarra
PSPhilippe Sarret
Philippe Sarret
Contulakins are a subclass of conopeptides derived from cone snail venom, known for their analgesic properties mediated through activation of neurotensin receptors NTS1 and NTS2. Among them, contulakin-G, isolated from Conus geographus, exhibits a favorable pharmacokinetic profile, including a 24-hour plasma half-life, and produces potent opioid-independent antinociceptive effects. To facilitate synthesis while preserving analgesic efficacy, we investigated the structure-activity relationships of contulakin-G, focusing on modifications to the glycosylated Thr10 residue. In the first series, Thr10 was substituted by natural and non-natural amino acids encompassing diverse physiochemical and steric properties. Most substitutions had minimal impact on receptor affinity, though some increased the NTS2/NTS1 selectivity ratio. Of these, only the Tyr10 analog retained antinociceptive efficacy comparable to native contulakin-G. Building on tyrosine's hydrophobicity, a second series introduced non-natural hydrophobic residues at position 10, including Gln-cycloheptyl, Gln-biphenylmethyl, and Gln-dimethyladamantyl, along with a non-glycosylated form. In both tonic and postoperative pain models, the non-glycosylated and Gln-cycloheptyl analogs demonstrated potent analgesic activity, comparable to contulakin-G and reversed mechanical allodynia in a neuropathic pain model. In contrast, a third series involving N-terminal truncations led to reduced plasma half-life and loss of antinociceptive efficacy, underscoring the importance of the N-terminal region. Molecular modeling further revealed that full-length analogs engage a broader NTS2 binding interface than truncated derivatives. These findings support the development of synthetically accessible contulakin-G analogs as promising non-opioid analgesics.

31 December 2025 in Acta Pharmaceutica Sinica B
Verified
Journal Article
Open access
RBRebecca L. Brouillette
Rebecca L. Brouillette
FLFrédérique Lussier
Frédérique Lussier
ÉBÉmile Breault
Émile Breault
NMNathan Meneboo
Nathan Meneboo
MHMalihe Hassanzadeh
Malihe Hassanzadeh
PSPhilippe Sarret
Philippe Sarret
Pepducins are synthetic membrane-tethered lipopeptides designed to allosterically modulate G protein-coupled receptor (GPCR) signaling. Here, we characterize a series of pepducins targeting the neurotensin receptor type 1 (NTSR1), revealing their complex and multifaceted modulation properties. Using BRET-based biosensors, we show that PP-001, a pepducin derived from NTSR1’s first intracellular loop, preferentially activates G protein over β-arrestin signaling while inhibiting NT binding, NT-induced β-arrestin recruitment, and NTSR1 internalization, thereby acting as biased allosteric agonist and negative allosteric modulator. PP-001 also promotes the formation of both homo- and heteromeric multi-receptor complexes. In vivo, PP-001 elicits potent, sustained hypotensive effects, reversible by the NTSR1 antagonist SR48692. Although the precise mechanism of pepducin-receptor interaction remains unclear, we identify a critical N-terminal RKK motif for PP-001’s biological activity. Finally, thermodenaturation assays using purified NTSR1, combined with mutagenesis and molecular docking, provide evidence for the role of the receptor’s H8 domain in direct pepducin interaction. Together, these findings highlight pepducins as versatile modulators of GPCR function and as valuable pharmacological tools for GPCR-targeted drug development.

11 May 2026 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
ÉBÉmile Breault
Émile Breault
JNJolien De Neve
Jolien De Neve
ARAmirmohammad Ranjbaran
Amirmohammad Ranjbaran
ATAlexandre Tremblay
Alexandre Tremblay
IRInes Robberechts
Ines Robberechts
PSPhilippe Sarret
Philippe Sarret
The ongoing opioid crisis underscores the urgent need for safer and more effective analgesics. One promising strategy involves designing bifunctional compounds that engage complementary antinociceptive systems to enhance efficacy while minimizing adverse effects. In this context, the neurotensin (NT) system is particularly attractive, as it produces long-lasting, opioid-independent analgesia and acts synergistically with opioid signaling. Here, we report the in vivo characterization of bifunctional opioid-neurotensin (OPNT) hybrid peptides, in which a dual MOP/DOP agonist is fused to a selective NTS2 agonist. These hybrids retained high affinity for MOP and DOP receptors, selective binding to NTS2 receptors, and partial agonist activity at MOP, a profile associated with reduced opioid-related liabilities. Among the series, SBL-OPNT-13 emerged as the lead compound, producing robust and sustained antinociceptive effects across multiple pain models, including acute thermal nociception, formalin-induced pain, postoperative hypersensitivity, and chronic inflammatory pain. Following intraperitoneal administration, SBL-OPNT-13 outperformed morphine, displaying greater potency and a prolonged duration of action lasting up to 24 h. Importantly, SBL-OPNT-13 was shown to cross the blood-brain barrier, supporting the role of the opioid pharmacophore as a shuttle for brain delivery of the NT moiety. From a safety perspective, SBL-OPNT-13 displayed reduced NTS1-mediated effects, such as hypotension and hypothermia, compared with earlier OPNT hybrids. Although opioid constipation was observed, repeated intrathecal administration resulted in partial tolerance, with a substantial residual antinociceptive effect, potentially reflecting the contribution of the NT pharmacophore. Together, these findings validate the dual-target strategy and identify SBL-OPNT-13 as a promising next-generation analgesic.

17 February 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
ÉBÉmile Breault
Émile Breault
RBRebecca Brouillette
Rebecca Brouillette
THTerry Hebert
Terry Hebert
PSPhilippe Sarret
Philippe Sarret
Elie Besserer-OffroyElie Besserer-Offroy
Elie Besserer-Offroy
Opioid analgesics have been used for more than 5,000 years and remain the main pain medications prescribed today. Although morphine is considered the gold standard of pain relief, this selective µ-opioid receptor (MOP) agonist provides only moderate relief for many chronic pain conditions, and produces a number of unwanted effects that can affect the patient’s quality-of-life, prevent adherence to treatment or lead to addiction. In addition to the lack of progress in developing better analgesics, there have been no significant breakthroughs to date in combating the above-mentioned side effects. Fortunately, a better understanding of opioid pharmacology has given renewed hope for the development of better and safer pain medications. In this review, we describe how clinically approved opioids were initially characterized as biased ligands and what impact this approach might have on clinical practice. We also looked at the preclinical and clinical development of biased MOP agonists, focusing on the history of oliceridine, the first specifically designed biased analgesic. In addition, we explore the discrepancies between ligands with low intrinsic efficacy and those with biased properties. Finally, we examine the rationale behind the development of biased ligands during the opioid crisis.